In the A549 human lung adenocarcinoma cell line, 24 h following treatment with Brachyury-specific siRNA, no significant difference in the proliferative capacity of each group was observed (P>0.05; Fig. 4A and B). This evidence concerns the gene TBX1 and lung adenocarcinoma.